P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort

Authors :: Beatriz Jimenez
Marina Chiara Garassino
Diego Signorelli
Domenico Galetta
Andrea Camerini
Giuseppe Luigi Banna
Giannis Mountzios
A. Calles Blanco
J. Rey-Cobo
Panagiotis Baxevanos
Marco Banini
Paris Kosmidis
G. Lo Russo
A. Christopoulou
Ana Collazo-Lorduy
Fausto Roila
A. De Toma
Alfredo Addeo
Giulio Metro
Panagiota Economopoulou
Helena Linardou
Source :: Journal of Thoracic Oncology. 14:S589
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Internal medicine
Cohort
medicine
In patient
Pd l1 expression
Pembrolizumab
business
Real world data

Tools